comparemela.com
Latest Breaking News On - Ose2101 - Page 1 : comparemela.com
OSE2101 Cancer Vaccine Yields Favorable OS vs SOC in HLA-A*02+ ICI-Resistant NSCLC
Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine.
Villejuif
France-general
France
Benjamin-besse
Institute-gustave-roussy
Ose2101-
Cancer-vaccine
Nsclc
Atalante-1-trial
Hlaa-02
vimarsana © 2020. All Rights Reserved.